Sana Q3 2021 Earnings Report
Key Takeaways
Sana Biotechnology reported a net loss of $83.3 million, or $0.46 per share, for the third quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $866.1 million as of September 30, 2021. Sana also announced a license agreement for Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs.
Announced license agreement for Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs.
Cash position of $866.1 million as of September 30, 2021.
Progressing pipeline and growing people and capabilities.
Looking forward to presenting data from in vivo CAR T and ex vivo allogeneic CAR T cell programs at ASH Annual Meeting & Exposition in December.
Sana
Sana
Forward Guidance
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws.